blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2676663

EP2676663 - TRANSDERMAL DELIVERY SYSTEM CONTAINING GALANTAMINE OR SALTS THEREOF [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  29.03.2019
Database last updated on 29.10.2024
FormerThe patent has been granted
Status updated on  20.04.2018
FormerGrant of patent is intended
Status updated on  18.12.2017
Most recent event   Tooltip01.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 03.08.2022  [2022/31]
Applicant(s)For all designated states
Industry-Academic Cooperation Foundation, Chosun University
375, Seosuk-dong
Dong-gu
Gwangju-city 501-759 / KR
For all designated states
TAHO Pharmaceuticals Ltd.
20F, No. 189, Sec. 2
Keelung Road
Taipei
110 / TW
[2018/21]
Former [2014/11]For all designated states
Industry-academic Cooperation Foundation, Chosun University
375, Seosuk-dong Dong-gu
Gwangju 501-759 / KR
For all designated states
TAHO Pharmaceuticals Ltd.
20F, No. 189, Sec. 2
Keelung Road
Taipei
110 / TW
Former [2014/10]For all designated states
TAHO Pharmaceuticals Ltd.
20F, No. 189, Sec. 2
Keelung Road
Taipei
110 / TW
Former [2013/52]For all designated states
Industry-academic Cooperation Foundation, Chosun University
375, Seosuk-dong Dong-gu
Gwangju 501-759 / KR
Inventor(s)01 / CHOI, Hoo-Kyun
3-1408 Pyeonghwa Mansion
768 Hak-dong
Dong-gu
Gwangju 501-847 / KR
02 / CHUN, Myung-Kwan
501 Sewon Bldg.
1196-5 Gaepo 4-dong
Gangnam-gu
Seoul 135-962 / KR
 [2013/52]
Representative(s)Becker Kurig & Partner Patentanwälte mbB
Bavariastraße 7
80336 München / DE
[N/P]
Former [2018/21]Becker Kurig Straus
Patentanwälte
Bavariastrasse 7
80336 München / DE
Former [2013/52]Becker Kurig Straus
Patentanwälte Bavariastrasse 7
80336 München / DE
Application number, filing date12746904.717.02.2012
[2018/21]
WO2012KR01186
Priority number, dateKR2011001453018.02.2011         Original published format: KR 20110014530
[2013/52]
Filing languageKO
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2012111996
Date:23.08.2012
Language:KO
[2012/34]
Type: A2 Application without search report 
No.:EP2676663
Date:25.12.2013
Language:EN
[2013/52]
Type: B1 Patent specification 
No.:EP2676663
Date:23.05.2018
Language:EN
[2018/21]
Search report(s)International search report - published on:KR26.10.2012
(Supplementary) European search report - dispatched on:EP08.05.2015
ClassificationIPC:A61K9/70, A61K47/30, A61K31/55
[2013/52]
CPC:
A61K31/55 (EP,KR,US); A61K9/70 (EP,KR,US); A61K47/14 (US);
A61K47/30 (KR); A61K47/32 (US); A61K9/7023 (US);
A61K9/7053 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2013/52]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:TRANSDERMALES ABGABESYSTEM MIT GALANTAMIN ODER SALZEN DAVON[2013/52]
English:TRANSDERMAL DELIVERY SYSTEM CONTAINING GALANTAMINE OR SALTS THEREOF[2013/52]
French:ADMINISTRATION TRANSDERMIQUE CONTENANT DE LA GALANTAMINE OU SES SELS[2013/52]
Entry into regional phase16.08.2013Translation filed 
16.08.2013National basic fee paid 
16.08.2013Search fee paid 
16.08.2013Designation fee(s) paid 
16.08.2013Examination fee paid 
Examination procedure16.08.2013Examination requested  [2013/52]
04.12.2015Amendment by applicant (claims and/or description)
19.12.2017Communication of intention to grant the patent
09.04.2018Fee for grant paid
09.04.2018Fee for publishing/printing paid
09.04.2018Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  19.12.2017
Opposition(s)26.02.2019No opposition filed within time limit [2019/18]
Fees paidRenewal fee
28.02.2014Renewal fee patent year 03
03.02.2015Renewal fee patent year 04
17.02.2016Renewal fee patent year 05
16.01.2017Renewal fee patent year 06
18.01.2018Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU17.02.2012
AL23.05.2018
AT23.05.2018
CY23.05.2018
CZ23.05.2018
DK23.05.2018
EE23.05.2018
ES23.05.2018
FI23.05.2018
HR23.05.2018
IT23.05.2018
LT23.05.2018
LV23.05.2018
MC23.05.2018
MK23.05.2018
NL23.05.2018
PL23.05.2018
RO23.05.2018
RS23.05.2018
SE23.05.2018
SI23.05.2018
SK23.05.2018
SM23.05.2018
TR23.05.2018
BG23.08.2018
NO23.08.2018
GR24.08.2018
IS23.09.2018
PT24.09.2018
GB17.02.2019
IE17.02.2019
LU17.02.2019
MT17.02.2019
[2022/31]
Former [2021/32]HU17.02.2012
AL23.05.2018
AT23.05.2018
CY23.05.2018
CZ23.05.2018
DK23.05.2018
EE23.05.2018
ES23.05.2018
FI23.05.2018
HR23.05.2018
IT23.05.2018
LT23.05.2018
LV23.05.2018
MC23.05.2018
NL23.05.2018
PL23.05.2018
RO23.05.2018
RS23.05.2018
SE23.05.2018
SI23.05.2018
SK23.05.2018
SM23.05.2018
TR23.05.2018
BG23.08.2018
NO23.08.2018
GR24.08.2018
IS23.09.2018
PT24.09.2018
GB17.02.2019
IE17.02.2019
LU17.02.2019
MT17.02.2019
Former [2021/31]AL23.05.2018
AT23.05.2018
CY23.05.2018
CZ23.05.2018
DK23.05.2018
EE23.05.2018
ES23.05.2018
FI23.05.2018
HR23.05.2018
IT23.05.2018
LT23.05.2018
LV23.05.2018
MC23.05.2018
NL23.05.2018
PL23.05.2018
RO23.05.2018
RS23.05.2018
SE23.05.2018
SI23.05.2018
SK23.05.2018
SM23.05.2018
TR23.05.2018
BG23.08.2018
NO23.08.2018
GR24.08.2018
IS23.09.2018
PT24.09.2018
GB17.02.2019
IE17.02.2019
LU17.02.2019
MT17.02.2019
Former [2021/26]AL23.05.2018
AT23.05.2018
CY23.05.2018
CZ23.05.2018
DK23.05.2018
EE23.05.2018
ES23.05.2018
FI23.05.2018
HR23.05.2018
IT23.05.2018
LT23.05.2018
LV23.05.2018
MC23.05.2018
NL23.05.2018
PL23.05.2018
RO23.05.2018
RS23.05.2018
SE23.05.2018
SI23.05.2018
SK23.05.2018
SM23.05.2018
TR23.05.2018
BG23.08.2018
NO23.08.2018
GR24.08.2018
PT24.09.2018
GB17.02.2019
IE17.02.2019
LU17.02.2019
MT17.02.2019
Former [2020/29]AL23.05.2018
AT23.05.2018
CZ23.05.2018
DK23.05.2018
EE23.05.2018
ES23.05.2018
FI23.05.2018
HR23.05.2018
IT23.05.2018
LT23.05.2018
LV23.05.2018
MC23.05.2018
NL23.05.2018
PL23.05.2018
RO23.05.2018
RS23.05.2018
SE23.05.2018
SI23.05.2018
SK23.05.2018
SM23.05.2018
TR23.05.2018
BG23.08.2018
NO23.08.2018
GR24.08.2018
PT24.09.2018
GB17.02.2019
IE17.02.2019
LU17.02.2019
MT17.02.2019
Former [2020/16]AL23.05.2018
AT23.05.2018
CZ23.05.2018
DK23.05.2018
EE23.05.2018
ES23.05.2018
FI23.05.2018
HR23.05.2018
IT23.05.2018
LT23.05.2018
LV23.05.2018
MC23.05.2018
NL23.05.2018
PL23.05.2018
RO23.05.2018
RS23.05.2018
SE23.05.2018
SI23.05.2018
SK23.05.2018
SM23.05.2018
TR23.05.2018
BG23.08.2018
NO23.08.2018
GR24.08.2018
GB17.02.2019
IE17.02.2019
LU17.02.2019
Former [2020/11]AL23.05.2018
AT23.05.2018
CZ23.05.2018
DK23.05.2018
EE23.05.2018
ES23.05.2018
FI23.05.2018
HR23.05.2018
IT23.05.2018
LT23.05.2018
LV23.05.2018
MC23.05.2018
NL23.05.2018
PL23.05.2018
RO23.05.2018
RS23.05.2018
SE23.05.2018
SI23.05.2018
SK23.05.2018
SM23.05.2018
BG23.08.2018
NO23.08.2018
GR24.08.2018
GB17.02.2019
IE17.02.2019
LU17.02.2019
Former [2020/09]AL23.05.2018
AT23.05.2018
CZ23.05.2018
DK23.05.2018
EE23.05.2018
ES23.05.2018
FI23.05.2018
HR23.05.2018
IT23.05.2018
LT23.05.2018
LV23.05.2018
MC23.05.2018
NL23.05.2018
PL23.05.2018
RO23.05.2018
RS23.05.2018
SE23.05.2018
SI23.05.2018
SK23.05.2018
SM23.05.2018
BG23.08.2018
NO23.08.2018
GR24.08.2018
IE17.02.2019
LU17.02.2019
Former [2019/51]AL23.05.2018
AT23.05.2018
CZ23.05.2018
DK23.05.2018
EE23.05.2018
ES23.05.2018
FI23.05.2018
HR23.05.2018
IT23.05.2018
LT23.05.2018
LV23.05.2018
MC23.05.2018
NL23.05.2018
PL23.05.2018
RO23.05.2018
RS23.05.2018
SE23.05.2018
SI23.05.2018
SK23.05.2018
SM23.05.2018
BG23.08.2018
NO23.08.2018
GR24.08.2018
LU17.02.2019
Former [2019/47]AT23.05.2018
CZ23.05.2018
DK23.05.2018
EE23.05.2018
ES23.05.2018
FI23.05.2018
HR23.05.2018
IT23.05.2018
LT23.05.2018
LV23.05.2018
MC23.05.2018
NL23.05.2018
PL23.05.2018
RO23.05.2018
RS23.05.2018
SE23.05.2018
SI23.05.2018
SK23.05.2018
SM23.05.2018
BG23.08.2018
NO23.08.2018
GR24.08.2018
LU17.02.2019
Former [2019/45]AT23.05.2018
CZ23.05.2018
DK23.05.2018
EE23.05.2018
ES23.05.2018
FI23.05.2018
HR23.05.2018
IT23.05.2018
LT23.05.2018
LV23.05.2018
MC23.05.2018
NL23.05.2018
PL23.05.2018
RO23.05.2018
RS23.05.2018
SE23.05.2018
SI23.05.2018
SK23.05.2018
SM23.05.2018
BG23.08.2018
NO23.08.2018
GR24.08.2018
Former [2019/26]AT23.05.2018
CZ23.05.2018
DK23.05.2018
EE23.05.2018
ES23.05.2018
FI23.05.2018
HR23.05.2018
IT23.05.2018
LT23.05.2018
LV23.05.2018
NL23.05.2018
PL23.05.2018
RO23.05.2018
RS23.05.2018
SE23.05.2018
SI23.05.2018
SK23.05.2018
SM23.05.2018
BG23.08.2018
NO23.08.2018
GR24.08.2018
Former [2019/11]AT23.05.2018
CZ23.05.2018
DK23.05.2018
EE23.05.2018
ES23.05.2018
FI23.05.2018
HR23.05.2018
IT23.05.2018
LT23.05.2018
LV23.05.2018
NL23.05.2018
PL23.05.2018
RO23.05.2018
RS23.05.2018
SE23.05.2018
SK23.05.2018
SM23.05.2018
BG23.08.2018
NO23.08.2018
GR24.08.2018
Former [2019/10]AT23.05.2018
CZ23.05.2018
DK23.05.2018
EE23.05.2018
ES23.05.2018
FI23.05.2018
HR23.05.2018
LT23.05.2018
LV23.05.2018
NL23.05.2018
PL23.05.2018
RO23.05.2018
RS23.05.2018
SE23.05.2018
SK23.05.2018
BG23.08.2018
NO23.08.2018
GR24.08.2018
Former [2019/09]DK23.05.2018
EE23.05.2018
ES23.05.2018
FI23.05.2018
HR23.05.2018
LT23.05.2018
LV23.05.2018
NL23.05.2018
RS23.05.2018
SE23.05.2018
BG23.08.2018
NO23.08.2018
GR24.08.2018
Former [2019/08]DK23.05.2018
ES23.05.2018
FI23.05.2018
HR23.05.2018
LT23.05.2018
LV23.05.2018
NL23.05.2018
RS23.05.2018
SE23.05.2018
BG23.08.2018
NO23.08.2018
GR24.08.2018
Former [2018/52]ES23.05.2018
FI23.05.2018
HR23.05.2018
LT23.05.2018
LV23.05.2018
NL23.05.2018
RS23.05.2018
SE23.05.2018
BG23.08.2018
NO23.08.2018
GR24.08.2018
Former [2018/51]ES23.05.2018
FI23.05.2018
HR23.05.2018
LT23.05.2018
LV23.05.2018
RS23.05.2018
SE23.05.2018
BG23.08.2018
NO23.08.2018
Former [2018/50]ES23.05.2018
FI23.05.2018
HR23.05.2018
LT23.05.2018
SE23.05.2018
BG23.08.2018
NO23.08.2018
Former [2018/49]ES23.05.2018
FI23.05.2018
LT23.05.2018
SE23.05.2018
BG23.08.2018
NO23.08.2018
Former [2018/47]ES23.05.2018
FI23.05.2018
LT23.05.2018
NO23.08.2018
Documents cited:Search[XI]US2005074487  (HSU TSUNG-MIN [US], et al) [X] 1-4,6,8,9 * paragraphs [0437] - [0444]; example 23; tables 78-81 * * claim - * * paragraphs [0135] - [0137] - [0238] , [0257] - [0267] *[I] 5,7,10,11;
 [XI]US2006257462  (JANSEN ROLF R [US], et al) [X] 1-5,10,11 * figure -; example -; claim - * * paragraphs [0033] - [0038] - [0057] , [0058] , [0063] - [0068] * [I] 6-9;
 [XI]WO2007035941  (ALZA CORP [US], et al) [X] 1-6,8-11 * paragraphs [0028] - [0031] - [0054] - [0065] * * example -; claim - * [I] 7
International search[A]US5089267  (HILLE THOMAS DR [DE], et al);
 [A]US5700480  (HILLE THOMAS [DE], et al);
 [A]US5932238  (OPITZ K [DE]);
 [A]US6558696  (HILLE THOMAS [DE], et al);
 [A]WO2007064407  (NOVARTIS AG [CH], et al)
by applicantUS5700480
 US2007104771
    - COYLE, J.; KERSHAW, P., "Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimers disease", BIOL. PSYCHIATRY, (2001), vol. 49, doi:doi:10.1016/S0006-3223(00)01101-X, pages 289 - 299, XP001098881

DOI:   http://dx.doi.org/10.1016/S0006-3223(00)01101-X
    - ZAROTSKY, V.; SRAMEK, J.J.; CUTLER, N.R., "Galantamine hydrobromide: an agent for Alzheimer's disease", AM. J. HEALTH-SYST. PHARM, (2001), vol. 60, pages 446 - 452
    - SCOTT, L.J.; GOA, K.L., "Galantamine: a review of its use in Alzheimer's disease", DRUGS, (2000), vol. 60, doi:doi:10.2165/00003495-200060050-00008, pages 1095 - 1122, XP009056233

DOI:   http://dx.doi.org/10.2165/00003495-200060050-00008
    - COREY-BLOOM, J, "Galantamine: a review of its use in Alzheimer's disease and vascular dementia", INT. J. CLIN. PRACT, (2003), vol. 57, pages 219 - 223, XP008050022
    - THOMAS, B.J.; FINNIN, F.C., "The transdermal revolution", DRUG DISCOV, (2004), vol. 9, pages 697 - 703
    - WALTERS, K.A.; WALKER, M.; OLEJNIK, O., "Non-ionic surfactant effects on hairless mouse skin permeability characteristics", J. PHARM. PHARMACOL, (1987), vol. 40, pages 525 - 529
    - WILLIAMS, A.C.; BARRY, B.W., "Permeation enhancers", ADV. DRUG DELIVER. REV, (2004), vol. 56, pages 603 - 618
    - ANG, C.; FEN, H.E.; SUB, H.E., "Pharmacokinetics of galantamine Hbr in plasma and brain of mice", CHIN. J. PHARM, (2006), vol. 37, pages 55 - 61
    - CHOI, H-K.; ANGELLO, J., "The Mathematical analysis and optimization of a flow through diffusion cell system", PHARM. RES, (1994), vol. 11, pages 595 - 599
    - SUBEDI, R.K.; JANG, J.H.; KIM, JAE-II; PARK, Y.J; CHOI, H.-K., "Formulation and evaluation of transdermal patch containing sibutramine", J. KOR. PHARM. SCI, (2010), vol. 40, pages 33 - 38
    - KIM, J.H.; CHO Y.-J.; CHOI, H.-K., "Effect of vehicles and pressure sensitive adhesives on the permeation of tacrine across hairless mouse skin", INT. J. PHARM, (2000), vol. 196, doi:doi:10.1016/S0378-5173(99)00449-4, pages 105 - 113, XP000998581

DOI:   http://dx.doi.org/10.1016/S0378-5173(99)00449-4
    - MORIMOTO, Y.; KOKUBO, T.; SUGIBAYASHI, K., "Diffusion of drug in acrylic type pressure sensitive adhesive matrix. II. Influence of interaction", J. CONTROL. RELEASE, (1992), vol. 18, doi:doi:10.1016/0168-3659(92)90180-Y, pages 113 - 121, XP000247008

DOI:   http://dx.doi.org/10.1016/0168-3659(92)90180-Y
    - SUBEDI, R.K.; JANG, J.H.; KIM, JAE-II; PARK, Y.J.; CHOI, H.-K., "Formulation and evaluation of transdermal patch containing sibutramine", J. KOR. PHARM. SCI, (2010), vol. 40, pages 33 - 38
    - FURUISHI, T.; LO, T.; FUKAMI, T.; SUZUKI, T.; TOMONO, K., "Formulation and in vitro evaluation of pentazocine transdermal delivery system", BIOL. PHARM. BULL, (2008), vol. 31, pages 1439 - 1443
    - WOKOVICH, A.M.; PRODDUTURI, S.; DOUB, W.H.; HUSSAIN, A.S.; BUHSE, L.F., "Transdermal delivery system (TDDS) adhesion as a critical safety, efficacy and quality attribute", EUR. J. PHARM. BIOPHARM, (2006), vol. 64, doi:doi:10.1016/j.ejpb.2006.03.009, pages 1 - 8, XP027997908

DOI:   http://dx.doi.org/10.1016/j.ejpb.2006.03.009
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.